title: Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
abstract: BACKGROUND
  Aldosterone stimulates cardiac collagen synthesis. Circulating biomarkers of collagen turnover provide a useful tool for the assessment of cardiac remodeling in patients with congestive heart failure and left ventricular systolic dysfunction after acute myocardial infarction.
  
  
  RESULTS
  In a substudy of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), which evaluated the effects of the selective aldosterone receptor antagonist eplerenone versus placebo, serum levels of collagen biomarkers were measured in 476 patients with congestive heart failure after acute myocardial infarction complicated with left ventricular systolic dysfunction. The combination of the type I collagen telopeptide and brain natriuretic peptide levels above median at baseline was associated with all-cause mortality and the composite end point of cardiovascular death or heart failure hospitalization, with hazard ratios of 2.49 (P=0.039) and 3.03 (P=0.002), respectively. During follow-up, levels of aminoterminal propeptide of type I and type III procollagen were found to be consistently lower in the eplerenone group and significantly lower beginning at 6 months.
  
  
  CONCLUSIONS
  Changes in biomarkers of collagen synthesis and degradation suggest that extracellular matrix remodeling is an active process in patients with congestive heart failure and left ventricular systolic dysfunction after acute myocardial infarction. High type I collagen telopeptide and high brain natriuretic peptide serum levels are associated with the highest event rate. Eplerenone suppresses post-acute myocardial infarction collagen turnover changes.
authors.affiliation: CHU de Nancy, Hôpital Jeanne d'Arc, Dommartin-lès-Toul, France.
authors.forename: Wafae
authors.initials: W
authors.lastname: Iraqi
authors.forename: Patrick
authors.initials: P
authors.lastname: Rossignol
authors.forename: Michael
authors.initials: M
authors.lastname: Angioi
authors.forename: Renaud
authors.initials: R
authors.lastname: Fay
authors.forename: Josette
authors.initials: J
authors.lastname: Nuée
authors.forename: Jean Marie
authors.initials: JM
authors.lastname: Ketelslegers
authors.forename: John
authors.initials: J
authors.lastname: Vincent
authors.forename: Bertram
authors.initials: B
authors.lastname: Pitt
authors.forename: Faiez
authors.initials: F
authors.lastname: Zannad
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000378:metabolism*; D024042:Collagen Type I / Q000378:metabolism; D024061:Collagen Type III / Q000378:metabolism; D016757:Death, Sudden, Cardiac / Q000453:epidemiology; D000077545:Eplerenone; D005109:Extracellular Matrix / Q000378:metabolism; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D010919:Placebos; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D013148:Spironolactone / Q000031:analogs & derivatives / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality
chemical_list: D015415:Biomarkers; D024042:Collagen Type I; D024061:Collagen Type III; D000451:Mineralocorticoid Receptor Antagonists; D010919:Placebos; D013148:Spironolactone; D000077545:Eplerenone